The FDA’s approval of a second HIV pre-exposure prophylaxis option and a Q&A about antiretroviral stewardship in inpatient practice were two of the most popular infectious disease stories last week.
Healio’s live coverage of IDWeek, which recently wrapped up in Washington, D.C., made up the rest of the week’s top stories.
FDA approves Descovy for HIV PrEP, excluding cisgender women
The FDA has approved Descovy as a second option for HIV pre-exposure prophylaxis, or PrEP, in at-risk adults and adolescents. The approval excludes patients who have receptive vaginal intercourse due to a lack of efficacy data in this population, the agency said. Read more.
Q&A: Antiretroviral stewardship in inpatient practice
Healio recently spoke to David Koren, PharmD, BCPS, AAHIVP, clinical pharmacist specialist in infectious diseases at Temple University Hospital, about implementing antiretroviral stewardship in inpatient practice. Koren co-authored a policy paper that seeks to bring awareness to the issue. Read more.
Omadacycline performs no differently in patients with diabetes, study shows
The efficacy and safety of the antibiotic omadacycline are comparable in patients with and without diabetes, according to an IDWeek presentation. Read more.
Cefiderocol noninferior to high-dose meropenem in phase 3 trial for nosocomial pneumonia
Cefiderocol, a novel siderophore cephalosporin, was noninferior to high-dose meropenem for the primary endpoint of all-cause mortality 14 days after treatment was started in patients with nosocomial pneumonia caused by gram-negative pathogens, according to results of a randomized phase 3 trial presented during IDWeek. Read more.
VIDEO: Experts spend ‘a day on the Hill’ during IDWeek
In this video from IDWeek, Carlos del Rio, MD, FIDSA, professor of medicine and chair of the department of global health at Emory University Rollins School of Public Health, discusses spending “a day on the Hill” meeting with Congressional representatives. Watch video.